Tools
Stock profile

BELITE BIO, INC (BLTE)

BLTE · Latest close $156.23 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$156.23
As of Nov 18, 2026
Tracked funds holding
5 of 149
2026 Q2 13F filings
Opened / added
2 / 2
vs previous quarter
Trimmed / exited
1
vs previous quarter

BELITE BIO, INC (BLTE) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds opening new positions, 2 funds adding, and 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $32.3M sold). Latest close $156.23 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 12, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-32.3M
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Paradigm Biocapital Advisors · RTW Investments · Deerfield Management — 5 tracked funds hold BLTE. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 50 sales ($32.3M). Insider trading

Often held alongside

SAVARA INC (SVRA) · ERASCA INC (ERAS) · TARSUS PHARMACEUTICALS INC (TARS) · Abivax S.A. (ABVX) · ALNYLAM PHARMACEUTICALS, INC. (ALNY) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Paradigm Biocapital Advisors3.55%1,232,877ADDED (+10.6%) Q3 filed Nov 16
RTW Investments0.94%715,332HELD Q3 filed Nov 16
Deerfield Management0.57%357,199ADDED (+17.5%) Q3 filed Nov 16
Maverick Capital0.54%396,311NEW Q3 filed Nov 16
OrbiMed Advisors0.04%13,300NEW Q3 filed Nov 16
Perceptive Advisors——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +10.8% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

193.6147.422024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding81 of 8,857 filers
Long-only filers among them81
Change vs 2026 Q1+6 net · 80 entered · 74 exited
Shares reported, all filers9,473,460
Reported value, all filers$1.4B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Net income · FY2025$-77.6M
Total assets · FY2025$780.6M
Shares outstanding39,339,960
Market cap (at latest close)$6.1B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.

Short interest

Shares short · Oct 15, 20261,267,440
Share of shares outstanding3.22%
Days to cover7.11

Shares short at recent settlements — Jul 31, 2026: 1.1M · Aug 14, 2026: 1.1M · Aug 31, 2026: 1.0M · Sep 15, 2026: 1.1M · Sep 30, 2026: 1.1M · Oct 15, 2026: 1.3M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 27 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Dec 31, 2025.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 50 sales by 3 insiders ($32.3M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 12, 2026Scholl Hendrik PeterChief Medical OfficerSell500$162.04$81.0KSEC filing
Nov 12, 2026Scholl Hendrik PeterChief Medical OfficerSell500$164.68$82.3KSEC filing
Nov 12, 2026Scholl Hendrik PeterChief Medical OfficerSell500$166.82$83.4KSEC filing
Nov 12, 2026Scholl Hendrik PeterChief Medical OfficerSell500$170.41$85.2KSEC filing
Oct 1, 2026Scholl Hendrik PeterChief Medical OfficerSell200$163.62$32.7KSEC filing
Oct 1, 2026Scholl Hendrik PeterChief Medical OfficerSell24$164.64$4.0KSEC filing
Oct 1, 2026Scholl Hendrik PeterChief Medical OfficerSell120$165.49$19.9KSEC filing
Oct 1, 2026Scholl Hendrik PeterChief Medical OfficerSell50$166.44$8.3KSEC filing
Oct 1, 2026Scholl Hendrik PeterChief Medical OfficerSell78$167.59$13.1KSEC filing
Oct 1, 2026Scholl Hendrik PeterChief Medical OfficerSell12$168.21$2.0KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 1, 2026Hendrik Peter SchollOfficer4,000$679.3KOct 1, 2026SEC filing
Aug 12, 2026Yu-Hsin LinCEO, Chairman126,800$22.5MAug 12, 2026SEC filing
Aug 12, 2026Hao-Yuan ChuangOfficer, Director93,800$16.7MAug 12, 2026SEC filing
Jun 18, 2026Dr. Hendrick P. SchollAffiliate10,000$1.5MJun 18, 2026SEC filing
Jun 16, 2026Dr. Hendrick P. SchollAffiliate10,000$1.4MJun 16, 2026SEC filing
Apr 15, 2026Nathan L. MataOfficer16,666$2.9MApr 15, 2026SEC filing
Apr 9, 2026Wan Shan Chenaffiliate10,196$2.2MApr 9, 2026SEC filing
Apr 9, 2026Yu-Hsin LinCEO, Chairman136,000$24.3MApr 9, 2026SEC filing
Apr 9, 2026Hao-Yuan ChuangOfficer, Director100,000$17.9MApr 9, 2026SEC filing
Oct 17, 2025Wan Shan ChenAffiliate9,550$1.2MOct 17, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
May 14, 2026Yu-Hsin LinSC 13G/A1,253,9353.1%Mar 31, 2026SEC filing
Feb 17, 2026Darwin Global Management, Ltd.SC 13G/A3,027,7048.1%Dec 31, 2025SEC filing
Dec 10, 2025Darwin Global Management, Ltd.SC 13G2,617,0947.0%Dec 3, 2025SEC filing
Jan 21, 2025Yu-Hsin LinSC 13G2,287,0707.1%Dec 31, 2024SEC filing
Jan 21, 2025Lin Bioscience International Ltd.SC 13G17,095,26353.7%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

Red Flags

· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%

Key figures

· Excess Accruals (Sloan) — Accruals ratio: 33.9% · Net income: $-77.6M · Operating cash flow: $-37.0M · Investing cash flow: $-305.1M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold BLTE — ranked by lift, the co-holding pattern described in Methodology: SAVARA INC (SVRA) · ERASCA INC (ERAS) · TARSUS PHARMACEUTICALS INC (TARS) · Abivax S.A. (ABVX) · ALNYLAM PHARMACEUTICALS, INC. (ALNY) · COGENT BIOSCIENCES INC (COGT) · DISC MEDICINE INC (IRON) · SPYRE THERAPEUTICS INC (SYRE).

Recent 8-K filings

No Form 8-K filings for this ticker in the index (Jan 2023 – present).

Related

SAVARA INC (SVRA) · Track Record: how the signals scored · Practice timing on BLTE

One email a week: the week’s new filings and research. Subscribe free

← BLSH  ·  BLZE →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.